Peter Goadsby (Professor of Neurology, Headache Group, King’s College Hospital, London, UK) discusses erenumab for the prevention of migraine, including the rationale, findings and clinical implications of the LIBERTY study.
1. Could you tell us a little about erenumab and its advantages compared with current oral preventative therapies in migraine? (0:12)
2. What clinical evidence has led to the positive CHMP opinion for erenumab for the prevention of migraine? (0:44)
3. What was the rationale for the LIBERTY study? (1:24)
4. What were the efficacy and safety findings of this study? (1:50)
5. What are the implications of these findings for clinical practice? (2:40)
Speaker disclosure: Peter Goadsby serves as a consultant for Amgen, Novartis, Eli Lilly, Teva Pharmaceuticals, Alder Biopharmaceuticals and Allergan.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Andrew Blumenfeld, AHS 2021: Combination use of OnabotulinumtoxinA and CGRP mAbs for Chronic Migraine
We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine. The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at […]
Richard Lipton, AHS 2021: COURAGE Study Results
touchNEUROLOGY met with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the COURAGE study results investigating the Migraine Buddy Application. The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!